A naukri.com initiative
Bloomberg Quint
1d
359
Image Credit: Bloomberg Quint
Piramal Pharma Q4 Review: Operationally Inline; FY25 Ends On A Strong Note, Says Motilal Oswal —Maintains Buy
- Piramal Pharma delivered in-line sales/Ebitda in Q4 FY25, but earnings were below the estimate due to impairment of certain intangible assets.
- Piramal Pharma maintained its guidance of $1.2 billion revenue with a 25% Ebitda margin in the CDMO segment by FY30.
- Motilal Oswal maintains 'Buy' rating on Piramal Pharma but cuts target price.
Read Full Article
21 Likes
For uninterrupted reading, download the app